Digital Outreach Intervention for Lung Cancer Screening
NCT ID: NCT04083859
Last Updated: 2025-06-25
Study Results
Results available
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
NA
Total Enrollment
26998 participants
Study Classification
INTERVENTIONAL
Study Start Date
2022-01-01
Study Completion Date
2024-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
mPATH-Lung (mobile Patient Technology for Health - Lung) is an innovative digital outreach program that identifies patients who qualify for lung cancer screening and helps them get screened. The study will: 1) Determine the effect of mPATH-Lung on receipt of lung cancer screening in a pragmatic randomized-controlled trial conducted with primary care patients in two large health networks, 2) Elucidate the drivers of patients' screening decisions and screening behavior; and 3) Explore implementation outcomes that will impact the sustainability and dissemination of mPATH-Lung using program data, surveys, and interviews.
This project will determine how mPATH-Lung affects patients' screening decisions and their completion of screening.
This project will determine how mPATH-Lung affects patients' screening decisions and their completion of screening.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Mobile Patient Health Technology Intervention for Improving Lung Cancer Screening Rates in Eligible High Risk Patients
NCT07322367
Lung Cancer
NOT_YET_RECRUITING
NA
Proactive Outreach and Shared Decision Making in Improving Lung Cancer Screening Rates in Primary Care Patients
NCT03929926
Lung Cancer
COMPLETED
NA
A Study to Develop a Strategy to Increase Lung Cancer Screening in Women Who May Be at Risk for Lung Cancer
NCT04848961
Smoking
ACTIVE_NOT_RECRUITING
EARLY_PHASE1
Enhancing Lung Cancer Screening Through Human-Centered Intervention
NCT06351085
Lung Cancer
RECRUITING
NA
The MyLungHealth Study Protocol: Engaging Patients to Enable Interoperable Lung Cancer Decision Support at Scale
NCT06338592
Lung Cancer
Lung Neoplasms/Diagnosis
ACTIVE_NOT_RECRUITING
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Primary Objective: Determine the effectiveness of mPATH-Lung on receipt of LCS in a randomized pragmatic clinical trial of 1318 patients recruited from two large health networks, Wake Forest Baptist Health and the University of North Carolina at Chapel Hill.
Secondary Objectives:
* Elucidate the drivers of patients' decisions to receive or forgo LCS through a values clarification exercise embedded within mPATH-Lung and supplemental semi-structured interviews of at least 50 patients.
* Assess several critical implementation outcomes (reach, acceptability, and appropriateness) to inform the sustainability and scalability of mPATH-Lung across diverse primary care settings
Secondary Objectives:
* Elucidate the drivers of patients' decisions to receive or forgo LCS through a values clarification exercise embedded within mPATH-Lung and supplemental semi-structured interviews of at least 50 patients.
* Assess several critical implementation outcomes (reach, acceptability, and appropriateness) to inform the sustainability and scalability of mPATH-Lung across diverse primary care settings
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Lung Cancer
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
SCREENING
Blinding Strategy
DOUBLE
Investigators
Outcome Assessors
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
mPATH-Lung
Participants randomized to the mPATH arm will be shown a 5-minute animated LCS decision aid video, personalized risk/benefit information, and a values clarification exercise. The participants in this group will be given an option to request a screening appointment via the program.
Group Type
EXPERIMENTAL
mPATH-Lung
Intervention Type
OTHER
A web-based program that determines patients eligibility for lung cancer screening (LCS), informs them of LCS, presents them with personalized risk-benefit information, helps them make a screening decision, and helps them schedule a LCS clinic appointment.
Usual care (CONTROL)
Participants randomized to the control arm will be advised that they qualified for lung cancer screening and directed to speak with their provider if interested. The web app then displayed a 5-minute video about exercise for lung health before ending. They will not be offered the opportunity to estimate their predicted benefits and harms of screening or to request a lung cancer screening visit.
Group Type
PLACEBO_COMPARATOR
Lung health video
Intervention Type
OTHER
Web-based video about guideline recommended exercise for lung health
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
mPATH-Lung
A web-based program that determines patients eligibility for lung cancer screening (LCS), informs them of LCS, presents them with personalized risk-benefit information, helps them make a screening decision, and helps them schedule a LCS clinic appointment.
Intervention Type
OTHER
Lung health video
Web-based video about guideline recommended exercise for lung health
Intervention Type
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Meet the Medicare criteria for lung cancer screening, as updated in February 2022:
* Age 50 - 77 years
* Smoked at least 20 pack years
* Current smoker or quit smoking within the past 15 years
* Be scheduled to see a primary care provider within the health network in the next 3-4 weeks
* Have a patient portal account or cellphone number listed in the electronic health record
* Age 50 - 77 years
* Smoked at least 20 pack years
* Current smoker or quit smoking within the past 15 years
* Be scheduled to see a primary care provider within the health network in the next 3-4 weeks
* Have a patient portal account or cellphone number listed in the electronic health record
Exclusion Criteria
* Patients flagged as needing a language interpreter in the electronic health record (electronic messages and intervention is delivered in English only).
* Those for whom lung cancer screening would be inappropriate:
* Prior history of lung cancer
* Chest CT within the last 12 months
* Those with medical conditions predicting shorter life expectancy
* Patients whose home address is not within the state of North Carolina. (Due to telehealth guidelines)
* Those for whom lung cancer screening would be inappropriate:
* Prior history of lung cancer
* Chest CT within the last 12 months
* Those with medical conditions predicting shorter life expectancy
* Patients whose home address is not within the state of North Carolina. (Due to telehealth guidelines)
Minimum Eligible Age
50 Years
Maximum Eligible Age
77 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of North Carolina, Chapel Hill
OTHER
Sponsor Role
collaborator
National Cancer Institute (NCI)
NIH
Sponsor Role
collaborator
Wake Forest University Health Sciences
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
David P Miller, MD, MS
Role: PRINCIPAL_INVESTIGATOR
Wake Forest University Health Sciences
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of North Carolina- Chapel Hill
Chapel Hill, North Carolina, United States
Site Status
Wake Forest Baptist Medical Center
Winston-Salem, North Carolina, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Viale PH. The American Cancer Society's Facts & Figures: 2020 Edition. J Adv Pract Oncol. 2020 Mar;11(2):135-136. doi: 10.6004/jadpro.2020.11.2.1. Epub 2020 Mar 1. No abstract available.
Reference Type
BACKGROUND
National Lung Screening Trial Research Team; Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM, Sicks JD. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011 Aug 4;365(5):395-409. doi: 10.1056/NEJMoa1102873. Epub 2011 Jun 29.
Reference Type
BACKGROUND
Pinsky PF, Church TR, Izmirlian G, Kramer BS. The National Lung Screening Trial: results stratified by demographics, smoking history, and lung cancer histology. Cancer. 2013 Nov 15;119(22):3976-83. doi: 10.1002/cncr.28326. Epub 2013 Aug 26.
Reference Type
BACKGROUND
Moyer VA; U.S. Preventive Services Task Force. Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014 Mar 4;160(5):330-8. doi: 10.7326/M13-2771.
Reference Type
BACKGROUND
Wender R, Fontham ET, Barrera E Jr, Colditz GA, Church TR, Ettinger DS, Etzioni R, Flowers CR, Gazelle GS, Kelsey DK, LaMonte SJ, Michaelson JS, Oeffinger KC, Shih YC, Sullivan DC, Travis W, Walter L, Wolf AM, Brawley OW, Smith RA. American Cancer Society lung cancer screening guidelines. CA Cancer J Clin. 2013 Mar-Apr;63(2):107-17. doi: 10.3322/caac.21172. Epub 2013 Jan 11.
Reference Type
BACKGROUND
Jaklitsch MT, Jacobson FL, Austin JH, Field JK, Jett JR, Keshavjee S, MacMahon H, Mulshine JL, Munden RF, Salgia R, Strauss GM, Swanson SJ, Travis WD, Sugarbaker DJ. The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups. J Thorac Cardiovasc Surg. 2012 Jul;144(1):33-8. doi: 10.1016/j.jtcvs.2012.05.060.
Reference Type
BACKGROUND
Centers for Medicare & Medicaid Services. Final National Coverage Determination on Screening for Lung Cancer with Low Dose Computed Tomography (LDCT) (CAG-00439N).; 2015. https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=274. Accessed November 10, 2015.
Reference Type
BACKGROUND
Jemal A, Fedewa SA. Lung Cancer Screening With Low-Dose Computed Tomography in the United States-2010 to 2015. JAMA Oncol. 2017 Sep 1;3(9):1278-1281. doi: 10.1001/jamaoncol.2016.6416.
Reference Type
BACKGROUND
Bach PB, Mirkin JN, Oliver TK, Azzoli CG, Berry DA, Brawley OW, Byers T, Colditz GA, Gould MK, Jett JR, Sabichi AL, Smith-Bindman R, Wood DE, Qaseem A, Detterbeck FC. Benefits and harms of CT screening for lung cancer: a systematic review. JAMA. 2012 Jun 13;307(22):2418-29. doi: 10.1001/jama.2012.5521.
Reference Type
BACKGROUND
Harris RP, Sheridan SL, Lewis CL, Barclay C, Vu MB, Kistler CE, Golin CE, DeFrank JT, Brewer NT. The harms of screening: a proposed taxonomy and application to lung cancer screening. JAMA Intern Med. 2014 Feb 1;174(2):281-5. doi: 10.1001/jamainternmed.2013.12745.
Reference Type
BACKGROUND
Veronesi G, Maisonneuve P, Bellomi M, Rampinelli C, Durli I, Bertolotti R, Spaggiari L. Estimating overdiagnosis in low-dose computed tomography screening for lung cancer: a cohort study. Ann Intern Med. 2012 Dec 4;157(11):776-84. doi: 10.7326/0003-4819-157-11-201212040-00005.
Reference Type
BACKGROUND
Patz EF Jr. Lung cancer screening, overdiagnosis bias, and reevaluation of the Mayo Lung Project. J Natl Cancer Inst. 2006 Jun 7;98(11):724-5. doi: 10.1093/jnci/djj226. No abstract available.
Reference Type
BACKGROUND
Kovalchik SA, Tammemagi M, Berg CD, Caporaso NE, Riley TL, Korch M, Silvestri GA, Chaturvedi AK, Katki HA. Targeting of low-dose CT screening according to the risk of lung-cancer death. N Engl J Med. 2013 Jul 18;369(3):245-254. doi: 10.1056/NEJMoa1301851.
Reference Type
BACKGROUND
Brenner A, Howard K, Lewis C, Sheridan S, Crutchfield T, Hawley S, Reuland D, Kistler C, Pignone M. Comparing 3 values clarification methods for colorectal cancer screening decision-making: a randomized trial in the US and Australia. J Gen Intern Med. 2014 Mar;29(3):507-13. doi: 10.1007/s11606-013-2701-0. Epub 2013 Nov 23.
Reference Type
BACKGROUND
Reuland DS, Cubillos L, Brenner AT, Harris RP, Minish B, Pignone MP. A pre-post study testing a lung cancer screening decision aid in primary care. BMC Med Inform Decis Mak. 2018 Jan 12;18(1):5. doi: 10.1186/s12911-018-0582-1.
Reference Type
BACKGROUND
Fagerlin A, Pignone M, Abhyankar P, Col N, Feldman-Stewart D, Gavaruzzi T, Kryworuchko J, Levin CA, Pieterse AH, Reyna V, Stiggelbout A, Scherer LD, Wills C, Witteman HO. Clarifying values: an updated review. BMC Med Inform Decis Mak. 2013;13 Suppl 2(Suppl 2):S8. doi: 10.1186/1472-6947-13-S2-S8. Epub 2013 Nov 29.
Reference Type
BACKGROUND
Elwyn G, O'Connor A, Stacey D, Volk R, Edwards A, Coulter A, Thomson R, Barratt A, Barry M, Bernstein S, Butow P, Clarke A, Entwistle V, Feldman-Stewart D, Holmes-Rovner M, Llewellyn-Thomas H, Moumjid N, Mulley A, Ruland C, Sepucha K, Sykes A, Whelan T; International Patient Decision Aids Standards (IPDAS) Collaboration. Developing a quality criteria framework for patient decision aids: online international Delphi consensus process. BMJ. 2006 Aug 26;333(7565):417. doi: 10.1136/bmj.38926.629329.AE. Epub 2006 Aug 14.
Reference Type
BACKGROUND
Edwards A, Elwyn G. Shared Decision-Making in Health Care: Achieving Evidence-Based Patient Choice. Oxford: Oxford University Press; 2009.
Reference Type
BACKGROUND
Carter-Harris L, Brandzel S, Wernli KJ, Roth JA, Buist DSM. A qualitative study exploring why individuals opt out of lung cancer screening. Fam Pract. 2017 Apr 1;34(2):239-244. doi: 10.1093/fampra/cmw146.
Reference Type
BACKGROUND
Ali N, Lifford KJ, Carter B, McRonald F, Yadegarfar G, Baldwin DR, Weller D, Hansell DM, Duffy SW, Field JK, Brain K. Barriers to uptake among high-risk individuals declining participation in lung cancer screening: a mixed methods analysis of the UK Lung Cancer Screening (UKLS) trial. BMJ Open. 2015 Jul 14;5(7):e008254. doi: 10.1136/bmjopen-2015-008254.
Reference Type
BACKGROUND
Lillie SE, Fu SS, Fabbrini AE, Rice KL, Clothier B, Nelson DB, Doro EA, Moughrabieh MA, Partin MR. What factors do patients consider most important in making lung cancer screening decisions? Findings from a demonstration project conducted in the Veterans Health Administration. Lung Cancer. 2017 Feb;104:38-44. doi: 10.1016/j.lungcan.2016.11.021. Epub 2016 Nov 29.
Reference Type
BACKGROUND
Quaife SL, Marlow LAV, McEwen A, Janes SM, Wardle J. Attitudes towards lung cancer screening in socioeconomically deprived and heavy smoking communities: informing screening communication. Health Expect. 2017 Aug;20(4):563-573. doi: 10.1111/hex.12481. Epub 2016 Jul 11.
Reference Type
BACKGROUND
Jonnalagadda S, Bergamo C, Lin JJ, Lurslurchachai L, Diefenbach M, Smith C, Nelson JE, Wisnivesky JP. Beliefs and attitudes about lung cancer screening among smokers. Lung Cancer. 2012 Sep;77(3):526-31. doi: 10.1016/j.lungcan.2012.05.095. Epub 2012 Jun 6.
Reference Type
BACKGROUND
Carter-Harris L, Ceppa DP, Hanna N, Rawl SM. Lung cancer screening: what do long-term smokers know and believe? Health Expect. 2017 Feb;20(1):59-68. doi: 10.1111/hex.12433. Epub 2015 Dec 23.
Reference Type
BACKGROUND
Roth JA, Carter-Harris L, Brandzel S, Buist DSM, Wernli KJ. A qualitative study exploring patient motivations for screening for lung cancer. PLoS One. 2018 Jul 5;13(7):e0196758. doi: 10.1371/journal.pone.0196758. eCollection 2018.
Reference Type
BACKGROUND
Triplette M, Kross EK, Mann BA, Elmore JG, Slatore CG, Shahrir S, Romine PE, Frederick PD, Crothers K. An Assessment of Primary Care and Pulmonary Provider Perspectives on Lung Cancer Screening. Ann Am Thorac Soc. 2018 Jan;15(1):69-75. doi: 10.1513/AnnalsATS.201705-392OC.
Reference Type
BACKGROUND
Kanodra NM, Pope C, Halbert CH, Silvestri GA, Rice LJ, Tanner NT. Primary Care Provider and Patient Perspectives on Lung Cancer Screening. A Qualitative Study. Ann Am Thorac Soc. 2016 Nov;13(11):1977-1982. doi: 10.1513/AnnalsATS.201604-286OC.
Reference Type
BACKGROUND
Rajupet S, Doshi D, Wisnivesky JP, Lin JJ. Attitudes About Lung Cancer Screening: Primary Care Providers Versus Specialists. Clin Lung Cancer. 2017 Nov;18(6):e417-e423. doi: 10.1016/j.cllc.2017.05.003. Epub 2017 May 10.
Reference Type
BACKGROUND
Henderson LM, Jones LM, Marsh MW, Brenner AT, Goldstein AO, Benefield TS, Greenwood-Hickman MA, Molina PL, Rivera MP, Reuland DS. Opinions, practice patterns, and perceived barriers to lung cancer screening among attending and resident primary care physicians. Risk Manag Healthc Policy. 2018 Jan 22;10:189-195. doi: 10.2147/RMHP.S143152. eCollection 2017.
Reference Type
BACKGROUND
Simmons VN, Gray JE, Schabath MB, Wilson LE, Quinn GP. High-risk community and primary care providers knowledge about and barriers to low-dose computed topography lung cancer screening. Lung Cancer. 2017 Apr;106:42-49. doi: 10.1016/j.lungcan.2017.01.012. Epub 2017 Jan 31.
Reference Type
BACKGROUND
Ersek JL, Eberth JM, McDonnell KK, Strayer SM, Sercy E, Cartmell KB, Friedman DB. Knowledge of, attitudes toward, and use of low-dose computed tomography for lung cancer screening among family physicians. Cancer. 2016 Aug 1;122(15):2324-31. doi: 10.1002/cncr.29944. Epub 2016 Jun 13.
Reference Type
BACKGROUND
Raz DJ, Wu GX, Consunji M, Nelson RA, Kim H, Sun CL, Sun V, Kim JY. The Effect of Primary Care Physician Knowledge of Lung Cancer Screening Guidelines on Perceptions and Utilization of Low-Dose Computed Tomography. Clin Lung Cancer. 2018 Jan;19(1):51-57. doi: 10.1016/j.cllc.2017.05.013. Epub 2017 Jun 1.
Reference Type
BACKGROUND
Lewis JA, Petty WJ, Tooze JA, Miller DP, Chiles C, Miller AA, Bellinger C, Weaver KE. Low-Dose CT Lung Cancer Screening Practices and Attitudes among Primary Care Providers at an Academic Medical Center. Cancer Epidemiol Biomarkers Prev. 2015 Apr;24(4):664-70. doi: 10.1158/1055-9965.EPI-14-1241. Epub 2015 Jan 22.
Reference Type
BACKGROUND
Raz DJ, Wu GX, Consunji M, Nelson R, Sun C, Erhunmwunsee L, Ferrell B, Sun V, Kim JY. Perceptions and Utilization of Lung Cancer Screening Among Primary Care Physicians. J Thorac Oncol. 2016 Nov;11(11):1856-1862. doi: 10.1016/j.jtho.2016.06.010. Epub 2016 Jun 23.
Reference Type
BACKGROUND
Carter-Harris L, Tan AS, Salloum RG, Young-Wolff KC. Patient-provider discussions about lung cancer screening pre- and post-guidelines: Health Information National Trends Survey (HINTS). Patient Educ Couns. 2016 Nov;99(11):1772-1777. doi: 10.1016/j.pec.2016.05.014. Epub 2016 May 17.
Reference Type
BACKGROUND
Brenner AT, Malo TL, Margolis M, Elston Lafata J, James S, Vu MB, Reuland DS. Evaluating Shared Decision Making for Lung Cancer Screening. JAMA Intern Med. 2018 Oct 1;178(10):1311-1316. doi: 10.1001/jamainternmed.2018.3054.
Reference Type
BACKGROUND
Volk RJ, Linder SK, Leal VB, Rabius V, Cinciripini PM, Kamath GR, Munden RF, Bevers TB. Feasibility of a patient decision aid about lung cancer screening with low-dose computed tomography. Prev Med. 2014 May;62:60-3. doi: 10.1016/j.ypmed.2014.02.006. Epub 2014 Feb 8.
Reference Type
BACKGROUND
Housten AJ, Lowenstein LM, Leal VB, Volk RJ. Responsiveness of a Brief Measure of Lung Cancer Screening Knowledge. J Cancer Educ. 2018 Aug;33(4):842-846. doi: 10.1007/s13187-016-1153-8.
Reference Type
BACKGROUND
Bellinger C, Pinsky P, Foley K, Case D, Dharod A, Miller D. Lung Cancer Screening Benefits and Harms Stratified by Patient Risk: Information to Improve Patient Decision Aids. Ann Am Thorac Soc. 2019 Apr;16(4):512-514. doi: 10.1513/AnnalsATS.201810-690RL. No abstract available.
Reference Type
BACKGROUND
Dharod A, Bellinger C, Foley K, Case LD, Miller D. The Reach and Feasibility of an Interactive Lung Cancer Screening Decision Aid Delivered by Patient Portal. Appl Clin Inform. 2019 Jan;10(1):19-27. doi: 10.1055/s-0038-1676807. Epub 2019 Jan 9.
Reference Type
BACKGROUND
Miller DP Jr, Weaver KE, Case LD, Babcock D, Lawler D, Denizard-Thompson N, Pignone MP, Spangler JG. Usability of a Novel Mobile Health iPad App by Vulnerable Populations. JMIR Mhealth Uhealth. 2017 Apr 11;5(4):e43. doi: 10.2196/mhealth.7268.
Reference Type
BACKGROUND
Katki HA, Kovalchik SA, Petito LC, Cheung LC, Jacobs E, Jemal A, Berg CD, Chaturvedi AK. Implications of Nine Risk Prediction Models for Selecting Ever-Smokers for Computed Tomography Lung Cancer Screening. Ann Intern Med. 2018 Jul 3;169(1):10-19. doi: 10.7326/M17-2701. Epub 2018 May 15.
Reference Type
BACKGROUND
Pinsky PF, Bellinger CR, Miller DP Jr. False-positive screens and lung cancer risk in the National Lung Screening Trial: Implications for shared decision-making. J Med Screen. 2018 Jun;25(2):110-112. doi: 10.1177/0969141317727771. Epub 2017 Sep 20.
Reference Type
BACKGROUND
Fagerlin A, Zikmund-Fisher BJ, Ubel PA. Helping patients decide: ten steps to better risk communication. J Natl Cancer Inst. 2011 Oct 5;103(19):1436-43. doi: 10.1093/jnci/djr318. Epub 2011 Sep 19.
Reference Type
BACKGROUND
Hawley ST, Zikmund-Fisher B, Ubel P, Jancovic A, Lucas T, Fagerlin A. The impact of the format of graphical presentation on health-related knowledge and treatment choices. Patient Educ Couns. 2008 Dec;73(3):448-55. doi: 10.1016/j.pec.2008.07.023. Epub 2008 Aug 27.
Reference Type
BACKGROUND
Hoffman AS, Hempstead AP, Housten AJ, Richards VF, Lowenstein LM, Leal VB, Volk RJ. Using a Patient Decision Aid Video to Assess Current and Former Smokers' Values About the Harms and Benefits of Lung Cancer Screening With Low-Dose Computed Tomography. MDM Policy Pract. 2018 Apr 19;3(1):2381468318769886. doi: 10.1177/2381468318769886. eCollection 2018 Jan-Jun.
Reference Type
BACKGROUND
Pignone MP, Howard K, Brenner AT, Crutchfield TM, Hawley ST, Lewis CL, Sheridan SL. Comparing 3 techniques for eliciting patient values for decision making about prostate-specific antigen screening: a randomized controlled trial. JAMA Intern Med. 2013 Mar 11;173(5):362-8. doi: 10.1001/jamainternmed.2013.2651.
Reference Type
BACKGROUND
Weiner BJ, Lewis CC, Stanick C, Powell BJ, Dorsey CN, Clary AS, Boynton MH, Halko H. Psychometric assessment of three newly developed implementation outcome measures. Implement Sci. 2017 Aug 29;12(1):108. doi: 10.1186/s13012-017-0635-3.
Reference Type
BACKGROUND
Lowenstein LM, Richards VF, Leal VB, Housten AJ, Bevers TB, Cantor SB, Cinciripini PM, Cofta-Woerpel LM, Escoto KH, Godoy MC, Linder SK, Munden RF, Volk RJ. A brief measure of Smokers' knowledge of lung cancer screening with low-dose computed tomography. Prev Med Rep. 2016 Jul 26;4:351-6. doi: 10.1016/j.pmedr.2016.07.008. eCollection 2016 Dec.
Reference Type
BACKGROUND
Bangor A, Kortum PT, Miller JT. An Empirical Evaluation of the System Usability Scale. Int J Human-Computer Interact. 2008;24(6):574-594. doi:10.1080/10447310802205776
Reference Type
BACKGROUND
Henderson LM, Marsh MW, Benefield TS, Jones LM, Reuland DS, Brenner AT, Goldstein AO, Molina PL, Maygarden SJ, Rivera MP. Opinions and Practices of Lung Cancer Screening by Physician Specialty. N C Med J. 2019 Jan-Feb;80(1):19-26. doi: 10.18043/ncm.80.1.19.
Reference Type
BACKGROUND
Miller DP, Snavely AC, Dharod A, Brenner AT, Wright E, Stradtman L, Bellinger CR, Bundy R, Volk RJ, Hamburger E, Ferrari RM, Randazzo A, Reuland DS. A Direct-to-Patient Digital Health Program for Lung Cancer Screening: A Randomized Clinical Trial. JAMA. 2025 Oct 20. doi: 10.1001/jama.2025.17281. Online ahead of print.
Reference Type
DERIVED
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Document Type: Informed Consent Form
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB00060382
Identifier Type: OTHER
Identifier Source: secondary_id
IRB00060382
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Emergency Department Lung Cancer URMFG Pilot
NCT04979169
COMPLETED
NA
Lung Cancer Screening: A Multilevel Intervention
NCT03862001
COMPLETED
NA
Using Connected Health to Increase Lung Cancer Screening
NCT04612946
COMPLETED
NA
Patient Navigation for Lung Cancer Screening in an Urban Safety-Net System
NCT02758054
COMPLETED
NA
Resilience Measurement in Older Adults With Late-Stage Lung Cancer
NCT04825912
COMPLETED
NA
Increasing Lung Cancer Screening Uptake Among Emergency Department Patients
NCT07287085
NOT_YET_RECRUITING
NA
Project PLUS Lung Cancer Screening Promotion
NCT05937399
COMPLETED
NA
Early Detection of Lung Cancer
NCT03181256
ACTIVE_NOT_RECRUITING
Support and Outreach to Increase Screening for Lung Cancer in Patients With a History of Smoking
NCT05679349
RECRUITING
NA
Lung Screening Study
NCT00006382
COMPLETED
NA
Health Education Approach to Lung Screening
NCT06070870
RECRUITING
NA
Advancing Lung Cancer Screening One Text at a Time
NCT07227480
NOT_YET_RECRUITING
NA
Integrating Telehealth to Advance Lung Cancer Screening
NCT06638554
RECRUITING
NA
Centralized Lung Cancer Screening Engagement in At-Risk Populations
NCT07216144
ENROLLING_BY_INVITATION
NA
Feasibility of Cell-Free DNA Liquid Biopsy in Screening High-Risk Patients for Lung Cancer
NCT05384769
RECRUITING
NA
Multilevel Interventions to Increase Adherence to Lung Cancer Screening
NCT05747443
ACTIVE_NOT_RECRUITING
NA
Evaluation of the Lung Nodule Sensitivity of Stationary Chest Tomosynthesis in Patients With Known Lung Nodules
NCT02075320
COMPLETED
NA
Precision Prevention Strategy to Increase Uptake and Engagement in Lung Cancer Screening and Smoking Cessation Treatment
NCT05627674
ENROLLING_BY_INVITATION
NA
Implementing Fragmentomics Into Real World Screening IntervenTions to Evaluate Clinical Utility Among Individuals With Elevated Risk for Lung Cancer
NCT06145750
COMPLETED
NA
The INSPIRE-Lung Study
NCT05824273
COMPLETED
NA
Development and Pilot Testing of a Clinical Informatics Lung Cancer Screening Intervention
NCT02962115
COMPLETED
NA
Mobile Health Application of Disease Self-Management in Non-Small Cell Lung Cancer Patients During Targeted Therapy
NCT05611450
UNKNOWN
NA
A Feasibility Study to Further the Development of Lung Cancer-based Precision Medicine
NCT02597738
ACTIVE_NOT_RECRUITING
NA
The Effect of Direct Referral for Fast CT Scan in Early Lung Cancer Detection in General Practice
NCT01527214
COMPLETED
NA
Screening for Lung Cancer in Current or Past Smokers With Chronic Obstructive Pulmonary Disease
NCT00512746
COMPLETED
NA